NCT01109069 - Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia | Biotech Hunter

Enrollment

199

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

April 26, 2019

Study Completion Date

April 26, 2019

Conditions

B-cell Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaDiffuse Well-differentiated Lymphocytic LymphomaB Cell LymphomaFollicular LymphomaMantle Cell LymphomaNon-Hodgkin's LymphomaWaldenstrom MacroglobulinemiaBurkitt LymphomaB-Cell Diffuse Lymphoma

Interventions

DRUG

PCI-32765

Dose based on parent protocol

Trial Locations (16)

10065

New York

11042

New Hyde Park

37203

Nashville

43210

Columbus

60637

University of Chicago, Chicago

75702

Tyler

77030

MD Anderson Cancer Center, Houston

Houston

94305

Stanford University, Stanford

Stanford

97477

Springfield

98684

Vancouver

98902

Yakima Valley Memorial Hospital/North Star Lodge, Yakima

02215

Boston

14642-0001

Rochester

05405

Fletcher Allen Health Care and University of Vermont, Burlington